Top Court Won't Consider Mylan's Patent Battle Over Amrix

Law360, New York (January 14, 2013, 5:05 PM EST) -- The U.S. Supreme Court on Monday declined Mylan Pharmaceuticals Inc.'s request to review a Federal Circuit decision upholding Cephalon Inc.'s patents for the muscle relaxant Amrix, which Mylan argued allows for a “flawed” expansion of patent rights.

The High Court denied Mylan's petition for a writ of certiorari seeking reversal of the Federal Circuit's determination that Cephalon's patents were not made obvious in view of prior art. Cephalon sued Mylan in 2009 to block the release of Mylan's generic version of Amrix, a drug that delivers...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.